​
​

Palisade Bio Stock (NASDAQ:PALI)

ForecastOwnershipFinancialsChart
Palisade Bio by TradingView

Previous Close

$3.61

52W Range

$3.30 - $22.35

50D Avg

$3.88

200D Avg

$5.95

Market Cap

$4.49M

Avg Vol (3M)

$64.30K

Beta

1.30

Div Yield

-

PALI Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

9

IPO Date

Mar 30, 2007

Website

PALI Performance

PALI Financial Summary

Dec 23Dec 22Dec 21
Revenue$250.00K--
Operating Income$-12.85M$-15.72M$-41.85M
Net Income$-12.32M$-12.80M$-27.27M
EBITDA$-12.84M$-15.15M$-44.28M
Basic EPS$-27.01$-14.54$-146.46
Diluted EPS$-27.01$-14.54$-145.87

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
ZVSAZyVersa Therapeutics, Inc.
VIRIVirios Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
EFTReFFECTOR Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
CYTOAltamira Therapeutics Ltd.
UNCYUnicycive Therapeutics, Inc.
ZURAZura Bio Limited
ENVBEnveric Biosciences, Inc.